these differentiators may be as small as how a transaction operates or information provided on a report or as large as the entire automation of a workflow that would otherwise be completed manually . we intend to continue our focus on differentiating our products , and we carefully assess our investments regularly as we strive to assure those investments provide the solutions most valuable to our customers . deliver our solutions to new markets . areas of healthcare where work is done manually may benefit from our existing solutions . these areas include hospitals that continue to utilize manual operations , healthcare segments of the us market outside hospitals , and markets outside the us . we weigh the cost of entering these new markets against the expected benefits and focus on the markets that we believe are most likely to adopt our products . expansion of our solutions through acquisitions and partnerships . our acquisitions have generally been focused on automation of manual workflows or data analytics , which is the enhancement of data for our customers ' decision- 35 making processes . we believe that expansion of our product lines through acquisition and partnerships to meet our customers changing and evolving expectations is a key aspect to our historical and future success . since the sales cycle for many of our products can be as long as two years , and the installation cycle can be up to another year , the results of operations in 2013 were heavily influenced by our investment decisions that were made several years ago . we believe those investments are directly attributable to our revenue growth of 21 % and our net income growth of 48 % in 2013 as compared to 2012. our investments have been consistent with the strategies outlined above . to differentiate our solutions from others available in the market , we began shipping a refresh of our product line in 2011 which we market as g4 . the g4 refresh included multiple new products and an upgrade product that allowed existing customers to augment their installations to obtain the most current technology that we provide . the g4 product refresh has been a key contributor to our growth , with 37.0 % of our acute care installed base ordering upgrades to their existing systems since the announcement of g4 . in addition to enhanced capabilities , we have focused on attaining the highest quality and service measurements for g4 in the industry , while marketing the solution to new and existing customers . our research and development efforts today are designed to bring new products to market beyond the g4 product line that we believe will meet customer needs in years to come . consistent with our strategy to enter new markets , we have made investments in our sales , general , and administrative expenses to expand our sales team and market to new customers . our international efforts have focused primarily on three markets : china , where we made a mandarin version of our automated dispensing systems available in 2011 , the middle eastern countries of the arabian peninsula where new healthcare facility construction is taking place , and in the united kingdom where , in the third quarter of 2012 , we purchased 15 % of our united kingdom distributor 's outstanding equity for approximately $ 0.9 million in cash to accelerate the adoption of medication and supply automation . in connection with the investment , we have the right , under certain circumstances , to appoint a member to this company 's board of directors as well as certain other voting rights and , therefore , we believe we have the ability to exert significant influence over this distributor 's operations . our proportionate equity share of the income of this distributor recognized in our financial statements for the year ended december 31 , 2013 was immaterial . we have also expanded our sales efforts to non-acute care customers in the united states which has allowed us to sell our automated dispensing solutions and other products to this market . expansion of our solutions through acquisitions and partnerships include our acquisition of mts in 2012 and a recently announced , but not completed , potential acquisition of surgichem limited from bupa care homes ( cfg ) plc . surgichem is a provider of medication adherence products in the united kingdom . if completed , the combination of surgichem with omnicell is expected to enable both entities to sell their lines of proven multi- and single-dose products across a broader medication adherence packaging market in the united kingdom . we have also developed relationships with major providers of hospital information management systems with the goal of enhancing the interoperability of our products with their systems . we believe that enhanced interoperability will help reduce implementation costs , time , and maintenance for shared clients , while providing new clinical workflows designed to enhance efficiency and patient safety . we believe that the success of our three leg strategy of differentiated products , expansion into new markets , and acquisition and partnership in future periods will be based on , among other factors : our expectation that the overall market demand for healthcare services will increase as the population grows , life expectancies continue to increase , the quality and availability of healthcare services increases ; our expectation that the environment of increased patient safety awareness , increased regulatory control and increased need for workflow efficiency through the adoption of technology in the healthcare industry will make our solutions a priority in the capital budgets of healthcare facilities ; and our belief that healthcare customers will continue to value a consultative customer experience from their suppliers . among other financial measures , we utilize product bookings and product backlog to assess the current success of our strategies . story_separator_special_tag under the market approach , we estimated the fair values of our reporting units based on financial information on companies that we deemed were comparable to our business . we made judgments about the comparability of publicly traded companies engaged in similar businesses . we based our judgments on factors such as size , growth rates , profitability , and risk . based on publicly available information , we calculated the comparable companies ' market multiples of earnings before interest , taxes , depreciation and amortization , and stock option expense and factored in a control premium . the estimated fair values of our reporting units determined under the market approach exceeded their carrying values . finally , we compared the estimated fair values of our reporting units to our september 30 , 2013 total public market capitalization and assessed implied control premiums . based on the aforementioned , we concluded that the estimated fair value determined for both our reporting units was reasonable . in each case , the estimated fair values of our reporting units exceeded their respective carrying values and , as such , we concluded that goodwill assigned to our acute care and non-acute care segments was not impaired . in addition , we did not note any indications of goodwill impairment as of december 31 , 2013 . 39 in 2012 , we opted to perform a qualitative assessment of factors to determine if goodwill had been impaired as of december 31 , 2012. for both the acute care and non-acute care segments , we considered the following qualitative factors : macroeconomic conditions such as general economic conditions , limitations on accessing capital , fluctuations in foreign exchange rates or other developments in equity and credit markets ; industry and market considerations such as changes in the environment in which we operate , an increased competitive environment , a decline in market-dependent multiples or metrics ( consider in both absolute terms and relative to peers ) , a change in the market for our products or services , or a regulatory or political development ; cost factors such as increases in raw materials , labor , or other costs that have a negative effect on earnings and cash flows ; overall financial performance such as negative or declining cash flows or a decline in actual or planned revenue or earnings compared with actual and projected results of relevant prior periods ; other relevant entity-specific events such as changes in management , key personnel , strategy , or customers ; contemplation of bankruptcy or litigation ; and events affecting a reporting unit such as a change in the composition or carrying amount of its net assets , a more-likely-than-not expectation of selling or disposing all , or a portion , of a reporting unit , the testing for recoverability of a significant asset group within a reporting unit or recognition of a goodwill impairment loss in the financial statements of a subsidiary that is a component of a reporting unit . upon completion of our qualitative assessment conducted in the fourth quarter of 2012 , we concluded that it was more likely than not that the fair values of both the acute care and non-acute care segments exceeded their carrying values including the respective amounts of goodwill . in addition , management did not note any other indicators of goodwill impairment as of december 31 , 2012. we continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable . we review long-lived assets and certain purchased intangibles for impairment whenever events or changes in circumstances indicate that we will not be able to recover the asset 's carrying amount . recoverability of an asset is measured by comparing its carrying amount to the expected future undiscounted cash flows expected to result from the use and eventual disposition of that asset , excluding future interest costs that would be recognized as an expense when incurred . any impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair market value . significant management judgment is required in : identifying a triggering event that arises from a change in circumstances ; forecasting future operating results ; and estimating the proceeds from the disposition of long-lived or intangible assets . in future periods , material impairment charges could be necessary should different conditions prevail or different judgments be made . significant management judgment is also required for initial recognition and measurement of goodwill and other intangibles assets resulting from business combinations pursuant asc 805 , business combinations . management must assess the extent to which identified other intangibles assets are properly includable ( and with the appropriate fair value ) or properly excludable , by applying the recognition criteria . this judgment affects not only the other intangible assets but the remainder calculation of goodwill . the assessment of useful life for each acquired intangible asset impacts future financial position and operating performance through amortization expense . inventory . inventories are stated at the lower of cost ( utilizing standard costs ) , applying the first-in , first-out method , or market . we routinely assess our on-hand inventory for timely identification and measurement of obsolete , slow-moving or otherwise impaired inventory . we write down inventory for estimated obsolescence , excess or unmarketable quantities equal to the difference between the cost of the inventory and its estimated market value based on assumptions about future demand and market conditions . if actual future demand or market conditions are less favorable than we projected , additional inventory write-downs may be required . valuation of share-based awards . we account for share-based compensation in accordance with asc 718 , stock compensation . we estimate the fair value of our employee stock awards at the date of grant using certain subjective assumptions , such as expected volatility , which is based on a combination

cash flows the table below shows our cash flows for the years ended december 31 , 2013 , 2012 and 2011 : replace_table_token_15_th 46 2013 compared to 2012 net cash provided by operating activities . net cash provided by operating activities increased by $ 15.8 million in 2013 as compared to 2012. the major drivers increasing operating cash flow were an increase of $ 7.8 million in net income , a decrease of $ 5.9 million in sales-type leases , a decrease of $ 5.7 million in accounts receivable as a result of collection efforts , an increase of $ 5.0 million in non-cash expenses for depreciation and amortization primarily due to our new corporate headquarters and manufacturing site , and a decrease of $ 4.5 million in other assets . partially offsetting these increases in sources of operating cash flows were an increase of $ 7.9 million in inventories , and a decrease of $ 7.4 million in deferred gross profit . net cash used in investing activities . net cash used in investing activities decreased by $ 148.3 million in 2013 as compared to 2012 , primarily due to a decrease in acquisition activity in 2013. net cash provided by financing activities . net cash provided by financing activities represented an increase in cash of $ 7.6 million in 2013 as compared to 2012. the increase was primarily driven by an increase of $ 15.7 million in cash provided from shares issued under employee stock option exercises and stock purchase plans which was partially offset by an increase of $ 8.6 million cash used in stock repurchases . 2012 compared to 2011 net cash provided by operating activities . net cash provided by operating activities increased by $ 8.2 million in 2012 to $ 39.5 million from $ 31.2 million in 2011. the major drivers increasing operating cash flow were $ 5.8 million higher net income and a reduction of inventory of $ 12.0 million , as well as increases in accrued compensation of $ 4.7 million , deferred gross profit of $ 4.1 million and accounts payable of $ 4.0 million , between 2012 and 2011.


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows the table below shows our cash flows for the years ended december 31 , 2013 , 2012 and 2011 : replace_table_token_15_th 46 2013 compared to 2012 net cash provided by operating activities . net cash provided by operating activities increased by $ 15.8 million in 2013 as compared to 2012. the major drivers increasing operating cash flow were an increase of $ 7.8 million in net income , a decrease of $ 5.9 million in sales-type leases , a decrease of $ 5.7 million in accounts receivable as a result of collection efforts , an increase of $ 5.0 million in non-cash expenses for depreciation and amortization primarily due to our new corporate headquarters and manufacturing site , and a decrease of $ 4.5 million in other assets . partially offsetting these increases in sources of operating cash flows were an increase of $ 7.9 million in inventories , and a decrease of $ 7.4 million in deferred gross profit . net cash used in investing activities . net cash used in investing activities decreased by $ 148.3 million in 2013 as compared to 2012 , primarily due to a decrease in acquisition activity in 2013. net cash provided by financing activities . net cash provided by financing activities represented an increase in cash of $ 7.6 million in 2013 as compared to 2012. the increase was primarily driven by an increase of $ 15.7 million in cash provided from shares issued under employee stock option exercises and stock purchase plans which was partially offset by an increase of $ 8.6 million cash used in stock repurchases . 2012 compared to 2011 net cash provided by operating activities . net cash provided by operating activities increased by $ 8.2 million in 2012 to $ 39.5 million from $ 31.2 million in 2011. the major drivers increasing operating cash flow were $ 5.8 million higher net income and a reduction of inventory of $ 12.0 million , as well as increases in accrued compensation of $ 4.7 million , deferred gross profit of $ 4.1 million and accounts payable of $ 4.0 million , between 2012 and 2011.
```    
 Suspicious Activity Report : these differentiators may be as small as how a transaction operates or information provided on a report or as large as the entire automation of a workflow that would otherwise be completed manually . we intend to continue our focus on differentiating our products , and we carefully assess our investments regularly as we strive to assure those investments provide the solutions most valuable to our customers . deliver our solutions to new markets . areas of healthcare where work is done manually may benefit from our existing solutions . these areas include hospitals that continue to utilize manual operations , healthcare segments of the us market outside hospitals , and markets outside the us . we weigh the cost of entering these new markets against the expected benefits and focus on the markets that we believe are most likely to adopt our products . expansion of our solutions through acquisitions and partnerships . our acquisitions have generally been focused on automation of manual workflows or data analytics , which is the enhancement of data for our customers ' decision- 35 making processes . we believe that expansion of our product lines through acquisition and partnerships to meet our customers changing and evolving expectations is a key aspect to our historical and future success . since the sales cycle for many of our products can be as long as two years , and the installation cycle can be up to another year , the results of operations in 2013 were heavily influenced by our investment decisions that were made several years ago . we believe those investments are directly attributable to our revenue growth of 21 % and our net income growth of 48 % in 2013 as compared to 2012. our investments have been consistent with the strategies outlined above . to differentiate our solutions from others available in the market , we began shipping a refresh of our product line in 2011 which we market as g4 . the g4 refresh included multiple new products and an upgrade product that allowed existing customers to augment their installations to obtain the most current technology that we provide . the g4 product refresh has been a key contributor to our growth , with 37.0 % of our acute care installed base ordering upgrades to their existing systems since the announcement of g4 . in addition to enhanced capabilities , we have focused on attaining the highest quality and service measurements for g4 in the industry , while marketing the solution to new and existing customers . our research and development efforts today are designed to bring new products to market beyond the g4 product line that we believe will meet customer needs in years to come . consistent with our strategy to enter new markets , we have made investments in our sales , general , and administrative expenses to expand our sales team and market to new customers . our international efforts have focused primarily on three markets : china , where we made a mandarin version of our automated dispensing systems available in 2011 , the middle eastern countries of the arabian peninsula where new healthcare facility construction is taking place , and in the united kingdom where , in the third quarter of 2012 , we purchased 15 % of our united kingdom distributor 's outstanding equity for approximately $ 0.9 million in cash to accelerate the adoption of medication and supply automation . in connection with the investment , we have the right , under certain circumstances , to appoint a member to this company 's board of directors as well as certain other voting rights and , therefore , we believe we have the ability to exert significant influence over this distributor 's operations . our proportionate equity share of the income of this distributor recognized in our financial statements for the year ended december 31 , 2013 was immaterial . we have also expanded our sales efforts to non-acute care customers in the united states which has allowed us to sell our automated dispensing solutions and other products to this market . expansion of our solutions through acquisitions and partnerships include our acquisition of mts in 2012 and a recently announced , but not completed , potential acquisition of surgichem limited from bupa care homes ( cfg ) plc . surgichem is a provider of medication adherence products in the united kingdom . if completed , the combination of surgichem with omnicell is expected to enable both entities to sell their lines of proven multi- and single-dose products across a broader medication adherence packaging market in the united kingdom . we have also developed relationships with major providers of hospital information management systems with the goal of enhancing the interoperability of our products with their systems . we believe that enhanced interoperability will help reduce implementation costs , time , and maintenance for shared clients , while providing new clinical workflows designed to enhance efficiency and patient safety . we believe that the success of our three leg strategy of differentiated products , expansion into new markets , and acquisition and partnership in future periods will be based on , among other factors : our expectation that the overall market demand for healthcare services will increase as the population grows , life expectancies continue to increase , the quality and availability of healthcare services increases ; our expectation that the environment of increased patient safety awareness , increased regulatory control and increased need for workflow efficiency through the adoption of technology in the healthcare industry will make our solutions a priority in the capital budgets of healthcare facilities ; and our belief that healthcare customers will continue to value a consultative customer experience from their suppliers . among other financial measures , we utilize product bookings and product backlog to assess the current success of our strategies . story_separator_special_tag under the market approach , we estimated the fair values of our reporting units based on financial information on companies that we deemed were comparable to our business . we made judgments about the comparability of publicly traded companies engaged in similar businesses . we based our judgments on factors such as size , growth rates , profitability , and risk . based on publicly available information , we calculated the comparable companies ' market multiples of earnings before interest , taxes , depreciation and amortization , and stock option expense and factored in a control premium . the estimated fair values of our reporting units determined under the market approach exceeded their carrying values . finally , we compared the estimated fair values of our reporting units to our september 30 , 2013 total public market capitalization and assessed implied control premiums . based on the aforementioned , we concluded that the estimated fair value determined for both our reporting units was reasonable . in each case , the estimated fair values of our reporting units exceeded their respective carrying values and , as such , we concluded that goodwill assigned to our acute care and non-acute care segments was not impaired . in addition , we did not note any indications of goodwill impairment as of december 31 , 2013 . 39 in 2012 , we opted to perform a qualitative assessment of factors to determine if goodwill had been impaired as of december 31 , 2012. for both the acute care and non-acute care segments , we considered the following qualitative factors : macroeconomic conditions such as general economic conditions , limitations on accessing capital , fluctuations in foreign exchange rates or other developments in equity and credit markets ; industry and market considerations such as changes in the environment in which we operate , an increased competitive environment , a decline in market-dependent multiples or metrics ( consider in both absolute terms and relative to peers ) , a change in the market for our products or services , or a regulatory or political development ; cost factors such as increases in raw materials , labor , or other costs that have a negative effect on earnings and cash flows ; overall financial performance such as negative or declining cash flows or a decline in actual or planned revenue or earnings compared with actual and projected results of relevant prior periods ; other relevant entity-specific events such as changes in management , key personnel , strategy , or customers ; contemplation of bankruptcy or litigation ; and events affecting a reporting unit such as a change in the composition or carrying amount of its net assets , a more-likely-than-not expectation of selling or disposing all , or a portion , of a reporting unit , the testing for recoverability of a significant asset group within a reporting unit or recognition of a goodwill impairment loss in the financial statements of a subsidiary that is a component of a reporting unit . upon completion of our qualitative assessment conducted in the fourth quarter of 2012 , we concluded that it was more likely than not that the fair values of both the acute care and non-acute care segments exceeded their carrying values including the respective amounts of goodwill . in addition , management did not note any other indicators of goodwill impairment as of december 31 , 2012. we continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable . we review long-lived assets and certain purchased intangibles for impairment whenever events or changes in circumstances indicate that we will not be able to recover the asset 's carrying amount . recoverability of an asset is measured by comparing its carrying amount to the expected future undiscounted cash flows expected to result from the use and eventual disposition of that asset , excluding future interest costs that would be recognized as an expense when incurred . any impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair market value . significant management judgment is required in : identifying a triggering event that arises from a change in circumstances ; forecasting future operating results ; and estimating the proceeds from the disposition of long-lived or intangible assets . in future periods , material impairment charges could be necessary should different conditions prevail or different judgments be made . significant management judgment is also required for initial recognition and measurement of goodwill and other intangibles assets resulting from business combinations pursuant asc 805 , business combinations . management must assess the extent to which identified other intangibles assets are properly includable ( and with the appropriate fair value ) or properly excludable , by applying the recognition criteria . this judgment affects not only the other intangible assets but the remainder calculation of goodwill . the assessment of useful life for each acquired intangible asset impacts future financial position and operating performance through amortization expense . inventory . inventories are stated at the lower of cost ( utilizing standard costs ) , applying the first-in , first-out method , or market . we routinely assess our on-hand inventory for timely identification and measurement of obsolete , slow-moving or otherwise impaired inventory . we write down inventory for estimated obsolescence , excess or unmarketable quantities equal to the difference between the cost of the inventory and its estimated market value based on assumptions about future demand and market conditions . if actual future demand or market conditions are less favorable than we projected , additional inventory write-downs may be required . valuation of share-based awards . we account for share-based compensation in accordance with asc 718 , stock compensation . we estimate the fair value of our employee stock awards at the date of grant using certain subjective assumptions , such as expected volatility , which is based on a combination

